Leslie Ann Dupree
Family · Smithfield, NCNPI 1548891039
Payments from drug & device makers
Across 181 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$738
- Dendreon Pharmaceuticals LLC$639
- Sumitomo Pharma America, Inc.$314
- Endo Pharmaceuticals Inc.$262
- Johnson & Johnson$225
- AbbVie$210
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,31083%
- Education$66817%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 19 | $738 |
| Dendreon Pharmaceuticals LLC | 26 | $639 |
| Sumitomo Pharma America, Inc. | 18 | $314 |
| Endo Pharmaceuticals Inc. | 10 | $262 |
| Johnson & Johnson | 12 | $225 |
| AbbVie(2 entities) | 13 | $210 |
| Teleflex LLC | 8 | $201 |
| Bayer | 9 | $193 |
| Urovant Sciences Inc | 14 | $187 |
| Pfizer | 6 | $171 |
| Myovant Sciences Inc. | 8 | $165 |
| Urogen Pharma, Inc. | 6 | $105 |
| Convatec Inc. | 4 | $93 |
| Acerus Pharmaceuticals Corporation | 5 | $87 |
| Antares Pharma, Inc. | 5 | $86 |
| 180 Medical, Inc. | 3 | $70 |
| Merck | 3 | $49 |
| AstraZeneca | 2 | $33 |
| Boston Scientific | 2 | $29 |
| Olympus America Inc. | 1 | $28 |
| Clarus Therapeutics Inc. | 2 | $23 |
| Accord Healthcare, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Hollister Incorporated | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
How this compares
$3,979 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 185 | $131,666 |
| MyrbetriqMirabegron | 50 | $37,407 |
| Finasteride | 343 | $3,934 |
| Tamsulosin Hcl | 326 | $2,516 |
| NitrofurantoinNitrofurantoin Macrocrystal | 47 | $2,268 |
| Estradiol | 35 | $2,191 |
| Oxybutynin Chloride ErOxybutynin Chloride | 79 | $1,792 |
| Testosterone | 17 | $1,773 |
| Potassium Citrate ErPotassium Citrate | 21 | $1,591 |
| Testosterone Cypionate | 48 | $1,225 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $915 |
| Oxybutynin Chloride | 49 | $715 |
| Levofloxacin | 37 | $333 |
| Cephalexin | 22 | $261 |
| Dutasteride | 14 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $314 | $131,666185 claims |
| Astellas Pharma US IncMyrbetriq | $738 | $37,40750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Smithfield
- Linda WhiteSmithfield$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.